MARKET

ICCC

ICCC

Immucell
NASDAQ
7.41
-0.07
-0.93%
Closed 16:00 10/03 EDT
OPEN
7.50
PREV CLOSE
7.48
HIGH
7.70
LOW
7.41
VOLUME
3.79K
TURNOVER
--
52 WEEK HIGH
10.96
52 WEEK LOW
6.96
MARKET CAP
57.41M
P/E (TTM)
214.18
1D
5D
1M
3M
1Y
5Y
ImmuCell to Participate in the Lytham Partners Fall 2022 Investor Conference
PORTLAND, Maine, Sept. 14, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the hea...
GlobeNewswire · 09/14 21:00
BRIEF-Immucell Announces Unaudited Financial Results For The Quarter Ended June 30, 2022
BRIEF-Immucell Announces Unaudited Financial Results For The Quarter Ended June 30, 2022
Reuters · 08/11 20:19
Does ImmuCell (NASDAQ:ICCC) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Simply Wall St. · 08/05 13:24
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2022
Conference Call Scheduled for Friday, August 12, 2022 at 9:00 AM ETPORTLAND, Maine, Aug. 04, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets...
GlobeNewswire · 08/04 10:30
BRIEF-Immucell Receives Technical Section Incomplete Letter From FDA Pertaining To Re-Tain
BRIEF-Immucell Receives Technical Section Incomplete Letter From FDA Pertaining To Re-Tain
Reuters · 07/28 00:09
ImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain®
PORTLAND, Maine, July 27, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the heal...
GlobeNewswire · 07/28 00:05
BRIEF-Immucell Announces Preliminary Sales Results For Q2
BRIEF-Immucell Announces Preliminary Sales Results For Q2
Reuters · 07/07 12:01
ImmuCell announces preliminary 2Q sales of $3.9M
ImmuCell (NASDAQ:ICCC) announces <a href="https://seekingalpha.com/...
Seekingalpha · 07/07 10:58
More
About ICCC
ImmuCell Corporation is an animal health company. The Company is engaged in development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. It manufactures and markets the First Defense product line for the prevention of scours in newborn dairy and beef calves. It expanded this line into five different products with formulations targeting E. coli and coronavirus pathogens, as well as E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. These product line provides Immediate Immunity to newborn calves. The Company is engaged in development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. Its products reduce the use of traditional antibiotics in food producing animals.

Webull offers kinds of ImmuCell Corporation stock information, including NASDAQ:ICCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICCC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICCC stock methods without spending real money on the virtual paper trading platform.